EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer

First Results From SunRISe-1 in Patients With BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 in Combination With Cetrelimab, TAR-200, or Cetrelimab Alone

Neoadjuvant Pembrolizumab Shows Promise as Effective Systemic Therapy Prior to Radical Cystectomy for Cisplatin-Ineligible Muscle Invasive Bladder Cancer

Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (Doc): long-term results from 2 phase 3 trials from the STAMPEDE platform protocol

The Use of 68Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer

Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): Initial Report of a Randomized Controlled Trial

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy

The Hematuria Cancer Risk Score: A validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection

Infectious and Non-infectious Complications Following Prostate Biopsy: A Randomized Clinical Trial

Treatment duration and long-term safety and tolerability with darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study

Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CheckMate 274 trial

Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)

CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG)

Biology and performance of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline

The Tolerability and Efficacy of BCG Administration after Recurrence in Bladder-preserving Therapy For Muscle-invasive Bladder Cancer